Agentes quelantes sulfidrílicos: uma revisão
DOI:
https://doi.org/10.5902/2179460X27243Abstract
The increase industrial use of metais such as berilium, cadmium, copper, lead, magnesium and nickel results inevitably on a more contaminated environment. For this reason, environmental chronic poisonings with these metais have not been unusual and is a serious human health concern. Chelation therapy has been the basis for the medical treatment of metal poisoning for the past 4 decades. Chelating agents have been used clinically as antidotes for acute and chronic metal intoxications. These compounds enhance the excretion of toxic elements such as arsenic, cadmium, lead, or mercury, which are also well-known developmental toxicants. Moreover, they also decrease the metal's toxicity by preventing it from binding to cellular target molecules. However, there are many questions concerning the use of these compounds, including a wide range of overt and hidden undesirable side effects caused by these therapeutic dithiol chelating agents. The aspects pointed out above clearly indicate that more detailed experimental and clinical experiments are required to better establish the toxicological properties of BAL, DMPS and DMSA.Downloads
References
Aaseth, J., Jacobensem, D., Andersen, 0& Wickstrom, E. Treatment of mercury and lead poisoning with dimercaptosuccinic acid and sodium dimercaptopropanosulfate. Analyst. 120, 853-854 (1995).
Andersen, O. Oral cadmium exposure in mice: Toxicokinetics and efficiency of chelating agents. Toxicol. 20 (2): 83-112 (1989).
Aposhian, H.V. DMSA and DMPS- Water soluble antidotes for heavy metal poisoning. Ann. Rev.Pharmacol. Toxicol. 23: 193-215 (1983).
Aposhian, H.V, Carter, D.E., Hoover, T.D., Hsu, C.A., Maiorino, R.M. & Stine, E. DMSA, DMPS and DMPA as arsenic antidotes. Fundam.Appl.Toxicol. 4, S58-S70 (1984).
Aposhian, H.V & Aposhian, M.M. Meso-2,3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of na orally effective metal chelating agent. Ann. Rev. Pharmacol. Toxicol. 30, 279-306 (1990).
Aposhian, H.V, Maiorino, R.M., Rivera, M., Bruce, D.C., Dart, R.C., Hurlbut, K.M., Levine, D.J., Zheng, w., Quintus, F., Carter, D., Aposhian, M.M. Human studies with the chelating agents DMPS and DMSA. Clinical Toxicology. 30, 505-528 (1992).
Aposhian, M.M., Maiorino, R.M., Zhaofa, X. & Aposhian, HV Sodium 2,3-dimercapto-1-propanesulfonate (DMPS) treatment does not redistribute lead or mercury to the brain of rats. Toxicology. 109, 49-55 (1996).
Barbosa, N.BV, Rocha, J.B.T., Zeni, G., Emanuelli, T., Beque, M.C., Braga, A.L. Effect of organic selenium on d-aminolevulinate dehydratase from liver, kidney, and brain of adult rats. Toxicol. Appl. Pharmacol. 149, 243-253 (1998).
Bechara, E.J.H., Medeiros, M.H.G., Monteiro, H.P., Hermes-Lima, M., Pereira, B., Demasi, M., Costa, CA, Adballa, D.S.P., Onuki, J., Wendel, C.M.a, Masci, P.D. A free radical hypothesis of lead poisoning and inborn porphyrias associated with 5-aminolevulinic acid overload. Química Nova. 16, 385-392 (1993).
Buchet, J.P. & Lauwerys, R.R. Influence of 2,3 dimercaptopropane-1-sulfonate and dimercaptosuccinic acid on the mobilization of mercury from tissues of rats pretreated with mercuric chloride, phenylmercury acetate or mercury vapors. Toxicology 54, 323-333 (1989).
Campbell, J.R., Clarkson, T.w. & amar, M.D. The terapeutic use of 2,3-dimercaptopropane-1-sulfonate in two cases of inorganic mercury poisoning. J. Am. Med. Assoc. 256, 3127-3130 (1986).
Cantilena, L.R. & Klaassen, C.D. Comparison of the effectiveness of several chelators after single administration on the toxicity, excretion and distribution of cadmium. Toxicol. Appl. Pharmacol. 58,452-460 (1981).
Cantilena, L.R. & Klaassen, C.D. The effect of chelating agents on the excretion of endogenous metais. Toxicol. Appl, Pharmacol. 63, 344-350 (1982). 14.Chisolm, J.J.Jr. Poisoning due to heavy metais. Pediat. Clin. North. Amer. 17,591-615 (1970).
Chisolm, J.J.Jr. Evaluation of the potencial role of chelation therapy in treatment of low to moderate lead exposures. Environ. Health Perspect. 89, 67-74 (1990).
Chisolm, J.J.Jr. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children.Clin.Toxicol. 30(4), 493-504 (1992).
Cory-Slechta, D.A.; Weiss, B. & Cox, C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J. Pharmacol. Exp. Ther. 243, 804-813 (1987).
Cory-Slechta, D.A. Mobilization and redistribution of lead over the course of DMSA chelation therapy and long term efficacy. J.PharmacoI.Exp.Ther. 246, 84-91 (1988).
Dalhamn, T. & Friberg, F. Dimercaprol (2,3 dimercaptopropanol) in chronic cadmium poisoning. Acta Pharmacol. 11, 68 (1955).
Emanuelli, T., Rocha, J.B.T., Pereira, M.E., Porciuncula, L.O, Morsch, V.M., Martins, AF. & Souza, D.O. Effect of mercuric chloride intoxication and dimercaprol treatment on aminolevulinate dehydratase from brain, liver and kidney of adult mice. Pharmacol. & Toxicol. 79, 138-143 (1996).
Farina, M., Folmer, V., Andrade, L.H., Zeni, G., Bolzan, R.C., Braga, A.L., Rocha, J.B.T. Selenoxides inhibit d-aminolevulinic acid dehydratase. Toxicol. Lett. 119, 27-37 (2001).
Flora, S.J.S.; Mathur, Seema & Mathur, R. Effects of meso-2,3-dimercaptosuccinic acid or 2,3-dimercaptopropane 1-sulfonate on beryllium-induced biochemical alterations and metal concentration in male rats. Toxicology 95, 167-175 (1995).
Gilman, A., Philips, F.S., Allen, R.P. and Koelle, E.S. The treatment of acute cadmium intoxication in rabbits with 2,3-dimercaptopropanol (BAL) and other mercaptans. Chemical Warfare Service 87, 85-101 (1946).
Granick, S. & Mauzerall, D. Porphyrin biosynthesis in erythrocytes. II. Enzimes converting delta-aminolevulinic acid to coproporphyrinogen. J. Biol. Chem. 232,1119-1140 (1958).
Hoover, T.O. & Aposhian, H.V. BAL increases the arsenic-74 content of rabbit brain. Toxicol. Appl. Pharmacol. 70, 160-162 (1983).
Jennings, F.W, Atouguia, J.M. & Murray, M. Topical chemotherapy for experimental murine African CNS-trypanosomiasis: The successful use of the arsenical, melarsoprol combined with the 5-nitroimidazole, fexinidazole or MK-436. Tropical Medicine & International Health. 1, 590-598 (1996).
Jones, M.M. & Cherian, M.G. The search for chelate antagonists for chronic cadmium intoxication. Toxicology 6, :1-25 (1990).
Jugo, S. The efficiency of chelating agents in eliminating 203 Hg from the bodies of young and adult rats. Health Physics 38, 680-682 (1980).
Kappas, A., Sassa, S., Galbraith, R.A., Nordmann, Y. The Phorphyrias. In: The Metabolic Bases of Inherited Oisease, eds. Scriver, C.R., Beaudet, A.L., Sly, WS., Valle, O. (McGraw Hill, New York), pp. 2103-2160 (1995).
Klaassen, C.O. Heavy metais and heavy-metal antagonists. In: A.G. Gilman, L.S. Goodman, T.W. Rall and F. Murad (Eds), The Pharmacological Basis of Therapeutics, Macmillan, New York, pp. 1605-1627 (1985).
Klaassen, C.O. Heavy metais and heavy-metals antagonists. In: The Pharmacological Basis of Therapeutics, eds Gilman, AG; Rall, T.W; Nies, AS. & Taylor, P. 1592-1614. New York: Pergamon Press (1990).
Klaassen, C.O. Heavy metais and heavy-metals antagonists. In: The Pharmacological Basis of Therapeutics, Eds. Wonsiewicz, M.J. & McCurdy,P. pp.1649-1671. New York: McGraw-Hill, (1996).
Keith, R.L.; Setiarahardjo, 1.; Fernando, a.; Aposhian, H.V. & Gandolfi, A.J. Utilization of renal slices to evaluate the efficacy of chelating agents for removing mercury from the kidney. Toxicology 116,67-75 (1997).
Kostygou, N.M. Pharrnakol.Toksikol. 21, 64 (1958).
Longcope, WT., Luetscher, J.A., Wintrobe, M.M. & Juger, V. The treatment of arsenical dermatitis with preparations of BAL. J. Clin. Invest. 25, 528-533 (1946).
Mant, T.G.K.; Lewis, J.L.; Mattoo, T.K.; Ridgen, S.P.A.; Volans, G.N. & House, I.M.; Wakefield, A.J. & Cole, R.S. Mercury poisoning after disc-battery ingestion. Hum. Toxicol. 6 (2), 179-181 (1987).
Miller, A.L. Dimercaptosuccinic acid (DMSA), a non-toxic, watersoluble treatment for heavy metal toxicity. Altern. Med. Rev. 3(3), 199-207 (1998).
Muckter, H.; Liebl, B.; Reichl, FX.; Hunder, G.; Walther, U. & Fichtl, B. Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Hum. Exp. Toxicol. 16(8), 460-465 (1997).
Nogueira, C.W, Soares, FA, Bolzan, R.C., Jacques-Silva, M.C., Souza, D.O. and Rocha, J.B.T Investigations into the mechanism of 2,3-dimercaptopropanol neurotoxicity. Neurochemical Research 25, 1553-1558 (2000).
Nogueira, C.W, Rotta, L.N., Tavares, R.G., Souza, D.O. and Rocha, J.B.T. BAL modulates glutamate transport in synaptosomes and synaptic vesicles from rat brain. NeuroReport 12, 511-514 (2001).
Nogueira, C.W., Soares, FA., Nascimento, P.C., Muller, D., and Rocha, J.B.T. 2,3-dimercaptopropane-1-sulfonic acid and meso-2,3- dimercaptosuccinic acid increase mercury and cadmiuminduced inhibition of d-aminolevulinate dehydratase. Toxicology 184, 85-95 (2003a).
Nogueira, C. W, Santos FW., Soares, FA., Rocha, J.B.T 2,3-Dimercaptopropanol, 2,3-Dimercaptopropane-1-Sulfonic Acid and meso-2, 3-Dimercaptosuccinic Acid Inhibit d-Aminolevulinate Dehydratase from Human Erythrocytes in vitro Environmental Research 2003b in press.
Pappas, J.B.; Ahlquist, J.T.; Allen, E.M. & Banner, W.Jr. Oral dimercaptosuccinic acid and ongoing exposure to lead: Effects on Heme synthesis and lead distribution in a rat model. Toxicol. Appl. Pharmacol. 133, 121-129 (1995).
Pepin, J., Milord, F, Khonde Na, Niyonsenga, T, Loko, L., Mpia, B. & Dewals, P. Risk-factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma-Brucel-Gambiense sleeping sickness. Transactions of the Royal Society of Tropical Medicine and Hygiene. 89, 92-97(1995).
Rocha, J.B.T., Freitas, A.J., Marques, M.B., Pereira, M.E., Emanuelli, T., Souza, D.O. Effects of methylmercury exposure during the second stage of rapid postnatal brain growth on negative geotaxis and on delta-aminolevulinate dehydratase of suckling rats. Brazilian J. Med. Biol. Res. 26, 1077-1083 (1993).
Sassa, S., Fujita, H., Kappas, A. Genetic and chemical influences on heme biosynthesis. In: Kotyk, A., Skoda, J., Paces,V., Kostka, V. (Eds.), Highlights of Modern Biochemistry, Vol. 1. VSP, Utrecht, pp.329-338 (1989).
Shimada, H.; Fukudome, S.; Kiyozumi, M.; Funakoshi, T; Adachi, T; Yasutake, A. & Kojima, S. Further study of effects of chelating agents on excretion of inorganic mercury in rats. Toxicology 77, 157-169 (1993).
Singer, A.J.; Mofenson, H.C.; Caraccio, TR. & lIasi, J. Mercury chloride poisoning due to ingestion of a stool fixative.J.ToxicoI.Clin.Toxicol. 32(5), 577-582 (1994).
Stocken, L.A. & Thompson, R.S.H. British anti-Lewisite 3. Arsenic and thiol excretion in animais after treatment of Lewisite burns. Biochem. J. 40, 548-554 (1946).
Stocken, L.A. British anti-Lewisite as an antidote to acute mercury poisoning. Biochem.J. 41, 358-360 (1947).
Suzuki, S.; Takamura, S.; Sugiki, K.; Imai, M.; Niwa, O. & Tamatani, R. Protective effects of 2,3-dimercaptopropane-1-sulfonate on mercury chloride-induced acute inhibition of enzymes trom rat duodenal mucosa and kidney cortex. Toxicology 86, 29-48 (1994).
Toet, A.E.; Dijk, A.; Savelkoul, TJ.F. & Meulenbelt, J. Mercury kinetics in a case of severe mercuric chloride poisoning treated with dimercapto-1-propane sulphonate (DMPS). Human & Experimental Toxicology 13, 11-16 (1994).
Torre, A.; Belles, M.; Llobet, J.M.; Mayayo, E. & Domingo, J.L. Comparasion of the effectiveness of 2,3-dimercaptopropanol and meso-2,3-dimercaptosuccinic acid (DMSA) as protective agents against mercuric chloride-induced nephrotoxicity in rats. 8Io/. Trace Elem. Res. 63(1),1-10 (1998).
Wang, S.C.; Ting, K.S. & Wu, C.C. Clin. Med. J. 84, 437 (1965).
Downloads
Published
How to Cite
Issue
Section
License
To access the DECLARATION AND TRANSFER OF COPYRIGHT AUTHOR’S DECLARATION AND COPYRIGHT LICENSE click here.
Ethical Guidelines for Journal Publication
The Ciência e Natura journal is committed to ensuring ethics in publication and quality of articles.
Conformance to standards of ethical behavior is therefore expected of all parties involved: Authors, Editors, Reviewers, and the Publisher.
In particular,
Authors: Authors should present an objective discussion of the significance of research work as well as sufficient detail and references to permit others to replicate the experiments. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review Articles should also be objective, comprehensive, and accurate accounts of the state of the art. The Authors should ensure that their work is entirely original works, and if the work and/or words of others have been used, this has been appropriately acknowledged. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. Authors should not submit articles describing essentially the same research to more than one journal. The corresponding Author should ensure that there is a full consensus of all Co-authors in approving the final version of the paper and its submission for publication.
Editors: Editors should evaluate manuscripts exclusively on the basis of their academic merit. An Editor must not use unpublished information in the editor's own research without the express written consent of the Author. Editors should take reasonable responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper.
Reviewers: Any manuscripts received for review must be treated as confidential documents. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should be conducted objectively, and observations should be formulated clearly with supporting arguments, so that Authors can use them for improving the paper. Any selected Reviewer who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the Editor and excuse himself from the review process. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
